Figure 3 | Oncogene

Figure 3

From: SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo

Figure 3

Transcriptional and Western blot analysis of Suit-2-SEL1L clones. (a) RT-PCR analysis of RNA extracted from the Suit-2-pDEX.1 control clone uninduced and DEX-induced for 1 and 2 weeks (lanes 1–3), Suit-2-SEL1L clones 14 (lanes 4–6), 37 (lanes 7–9) and 10 (lanes 10–12). M is the marker. The induction of the 900 bp recombinant SEL1L transcript is evident as is the increased expression level of DPC4/Smad4 (565 bp) and activin A (395 bp) after DEX treatment, while the activin receptor II expression level remains unaltered. Equal amounts of synthesized cDNA were tested by HPRT primers. (b) Protein expression of SEL1L from Suit-2-pDEX.1 control clone before and after 1 and 2 weeks of DEX induction (lanes 1–3), from Suit-2-SEL1L clones 14 (lanes 4–6), 37 (lanes 7–9) and 10 (lanes 10–12). The lower band is likely to be an artifact observed in Western analysis as it is not induced and remains constant in level under all experimental conditions

Back to article page